LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Lyell Immunopharma Inc

Затворен

0.42 5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.4

Максимум

0.42

Ключови измерители

By Trading Economics

Приходи

140M

-52M

Продажби

-4K

7K

EPS

-0.18

Марж на печалбата

-745,642.857

Служители

300

EBITDA

58M

-119K

Препоръки

By TipRanks

Препоръки

Продай

12-месечна прогноза

+150% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1M

123M

Предишно отваряне

-4.58

Предишно затваряне

0.42

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Lyell Immunopharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.05.2025 г., 10:30 ч. UTC

Топ новини

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31.05.2025 г., 06:30 ч. UTC

Печалби

5 Things We've Learned From Retail Earnings -- Barrons.com

31.05.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 23:51 ч. UTC

Придобивния, сливания и поглъщания

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30.05.2025 г., 21:30 ч. UTC

Топ новини

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30.05.2025 г., 21:15 ч. UTC

Топ новини

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30.05.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

30.05.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30.05.2025 г., 20:24 ч. UTC

Топ новини

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30.05.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 19:44 ч. UTC

Пазарно говорене

Gold Breaks 4-Month Winning Streak -- Market Talk

30.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30.05.2025 г., 19:29 ч. UTC

Печалби
Придобивния, сливания и поглъщания

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30.05.2025 г., 19:14 ч. UTC

Пазарно говорене

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30.05.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30.05.2025 г., 18:51 ч. UTC

Пазарно говорене

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30.05.2025 г., 18:37 ч. UTC

Пазарно говорене
Печалби

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30.05.2025 г., 18:04 ч. UTC

Топ новини

S&P 500 Falls After More Trump-China Friction -- WSJ

30.05.2025 г., 17:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.05.2025 г., 17:47 ч. UTC

Пазарно говорене

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30.05.2025 г., 17:40 ч. UTC

Придобивния, сливания и поглъщания

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30.05.2025 г., 17:38 ч. UTC

Пазарно говорене

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30.05.2025 г., 17:31 ч. UTC

Пазарно говорене

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30.05.2025 г., 17:14 ч. UTC

Топ новини

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30.05.2025 г., 16:31 ч. UTC

Печалби

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30.05.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

30.05.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

30.05.2025 г., 16:16 ч. UTC

Топ новини

S&P 500 Falls After Trump Hits Out at China -- WSJ

30.05.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.05.2025 г., 16:14 ч. UTC

Топ новини

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Lyell Immunopharma Inc Прогноза

Ценова цел

By TipRanks

150% нагоре

12-месечна прогноза

Среден 1 USD  150%

Висок 1 USD

Нисък 1 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Lyell Immunopharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

3 ratings

0

Купи

2

Задържане

1

Продай

Техническа оценка

By Trading Central

0.4217 / 0.4691Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.